Tempus Review

Tempus is a healthcare technology platform that combines genomic sequencing, clinical data aggregation, and artificial intelligence to support precision medicine. Founded in 2015, the company collects and structures large volumes of real-world clinical and molecular data, enabling physicians to access relevant patient insights at the point of care. Its core offerings span genomic testing, data licensing, and AI-driven analytics tools. The platform is primarily used in oncology, where matching patients to appropriate therapies based on their molecular profiles is critical. Tempus operates a proprietary database of de-identified clinical and genomic records, which it uses to train machine learning models and surface treatment-relevant patterns. Clinicians can use the platform to compare a patient's molecular profile against historical cases to identify potential therapy options or clinical trial eligibility. Beyond direct clinical use, Tempus licenses its data and analytical infrastructure to life sciences companies, pharmaceutical firms, and academic researchers. These partners use Tempus datasets and AI tools to support drug discovery, clinical trial design, and patient stratification. The company also offers tools for radiology and cardiology, expanding its footprint beyond oncology. Tempus competes in the broader precision medicine and clinical genomics market alongside companies such as Foundation Medicine and Guardant Health. Its differentiation lies in the breadth of its multimodal data — combining genomic, imaging, and clinical records — and the AI layer built on top of that data. The company went public on the Nasdaq in 2024, reflecting growing institutional interest in AI-driven clinical decision support.